Bevacizumab: Bone of Contention in the Therapy of Glioblastoma
Abstract. Despite combined modality therapy, glioblastomas frequently relapse within months after diagnosis. A standard of care for recurrent glioblastoma is yet to be defined. Bevacizumab, an ...